Comparative Pharmacology
Head-to-head clinical analysis: DIENESTROL versus THEELIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIENESTROL versus THEELIN.
DIENESTROL vs THEELIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to effects similar to endogenous estrogens.
Estrogen receptor agonist; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and promoting estrogenic effects.
0.1 to 0.5 mg orally once daily for estrogen replacement therapy; 0.5 to 1.0 mg orally once daily for prostatic carcinoma.
Intramuscular: 0.22 to 1.1 mg (220 to 1100 mcg) once weekly for menopausal symptoms; 0.5 to 2 mg (500 to 2000 mcg) once weekly for prostatic carcinoma.
None Documented
None Documented
Terminal elimination half-life is approximately 24-48 hours, longer with hepatic impairment.
Clinical Note
moderateDienestrol + Etoricoxib
"Dienestrol may increase the thrombogenic activities of Etoricoxib."
Clinical Note
moderateDienestrol + Parecoxib
"Dienestrol may increase the thrombogenic activities of Parecoxib."
Clinical Note
moderateDienestrol + Voriconazole
"The metabolism of Voriconazole can be decreased when combined with Dienestrol."
Clinical Note
moderateDienestrol + Lumiracoxib
"Dienestrol may increase the thrombogenic activities of Lumiracoxib."
Terminal elimination half-life: 13–19 hours (mean 16 h); clinical context: supports once-daily dosing for estrogen replacement.
Primarily renal (40-60% as glucuronide conjugates) and biliary/fecal (30-50% with enterohepatic recycling).
Renal: ~50% as glucuronide and sulfate conjugates; fecal: ~30% via enterohepatic recirculation; biliary: ~20%.
Category C
Category C
Estrogen
Estrogen